Unlock instant, AI-driven research and patent intelligence for your innovation.

Fused ring gamma-amino acid derivatives and their preparation methods and applications in medicine

A compound and composition technology, applied in the field of fused ring γ-amino acid derivatives, can solve the problems of patients with abuse, low safety, and dependence

Active Publication Date: 2020-12-15
SICHUAN HAISCO PHARMA CO LTD
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, for gabapentin, the proportion of improving the pain of patients with diabetic peripheral neuropathy is about 60% (Acta Neurol. Scand. 101:359-371, 2000), for pregabalin, although its tolerance is better than gabapentin , but its safety is lower, and it has the possibility of abuse or making patients dependent (Am J Health SystPharm.2007; 64(14):1475-1482)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fused ring gamma-amino acid derivatives and their preparation methods and applications in medicine
  • Fused ring gamma-amino acid derivatives and their preparation methods and applications in medicine
  • Fused ring gamma-amino acid derivatives and their preparation methods and applications in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] (±)-(1R,6S,7R)-1-(Aminomethyl)bicyclo[4.1.0]heptane-7-carboxylic acid (Compound 1)

[0087] (±)-(1R,6S,7R)-1-(aminomethyl)bicyclo[4.1.0]heptane-7-carboxylic acid

[0088] (±)-(1R,6S,7S)-1-(aminomethyl)bicyclo[4.1.0]heptane-7-carboxylic acid (compound 1’)

[0089] (±)-(1R,6S,7S)-1-(aminomethyl)bicyclo[4.1.0]heptane-7-carboxylic acid

[0090]

[0091]

[0092] The first step: cyclohexene-1-methylamine (1B)

[0093] cyclohex-1-en-1-ylmethanamine

[0094]

[0095] Lithium aluminum tetrahydride (3.8g, 100mmol) was added to dry methyl tert-butyl ether (300mL), and cyclohexene-1-carbonitrile (1A) (6g, 56mmol) in methyl tert-butyl ether was added dropwise (300mL) solution, add reflux reaction for 1 hour, after cooling, add 1 equivalent of water, 1 equivalent of sodium hydroxide aqueous solution (15%), stir for 30 minutes, filter out the solid, filter cake with water (100mL) and methyl Wash with tert-butyl ether (100mL), separate the organic phase from the filtrate,...

Embodiment 2

[0137] (±)-(1R,5S,6R)-1-(aminomethyl)bicyclo[3.1.0]hexane-6-carboxylic acid (compound 2)

[0138] (±)-(1R,5S,6R)-1-(aminomethyl)bicyclo[3.1.0]hexane-6-carboxylic acid

[0139] (±)-(1R,5S,6S)-1-(aminomethyl)bicyclo[3.1.0]hexane-6-carboxylic acid (compound 2’)

[0140] (±)-(1R,5S,6S)-1-(aminomethyl)bicyclo[3.1.0]hexane-6-carboxylic acid

[0141]

[0142] The first step: cyclopent-1-en-1-ylmethylamine (2B)

[0143] cyclopent-1-en-1-ylmethanamine

[0144]

[0145] Lithium aluminum hydride (7.4g, 200mmol) was dissolved in methyl tert-butyl ether (400mL), and cyclopent-1-ene-1-carbonitrile (2A) (10g, 110mmol) was dissolved in methyl tert-butyl dropwise Base ether (400 mL) solution was heated to reflux for 1 hour after dropping. Cool to room temperature, add dropwise water (7.4mL), sodium hydroxide aqueous solution (15% (w%), 7.4mL) and water (15mL) successively under ice-water bath, filter with suction, dry with anhydrous sodium sulfate, filter, the filtrate reduces conce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a fused cyclic gamma-amino acid derivative, a preparation method of the fused cyclic gamma-amino acid derivative, and an application of the fused cyclic gamma-amino acid derivative to pharmaceuticals, and particularly relates to the fused cyclic gamma-amino acid derivative shown as in the formula (I), or a stereisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or co-crystal of the fused cyclic gamma-amino acid derivative, a pharmaceutical composition comprising the fused cyclic gamma-amino acid derivative, and the application of the compound or composition to the field of analgesia, wherein the definitions of various substituent groups in the formula (I) and the definitions in the description are the same.

Description

technical field [0001] The present invention relates to a fused ring γ-amino acid derivative represented by general formula (I), or its stereoisomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, and its drug Composition and use in the field of analgesia. Background technique [0002] Voltage-gated calcium channels are composed of α1 subunits and accessory proteins α2δ, β, and γ subunits. α2δ protein can regulate the density and voltage-dependent dynamics of calcium channels (Felix et al(199 7) J.Neuroscience 17:6884-6891; Klugbauer et al(1999) J.Neuroscience 19:684-691; Hobom et al. al (2000) Eur. J. Neuroscience 12:1217-1226; and Qin et al (2002) Mol. Pharmacol. 62:485-496). Compounds that exhibit high affinity binding to the voltage-dependent calcium channel subunit α2δ have been shown to be effective in the treatment of pain, such as pregabalin and gabapentin. In mammals, there are four subtypes of α2δ protein, each of which is encoded ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C229/50A61K31/195A61P25/04A61P29/00A61P25/06A61P25/08A61P25/22
CPCC07C229/28C07C229/50Y02P20/55
Inventor 李瑶李升肖至阳
Owner SICHUAN HAISCO PHARMA CO LTD